ERBB2 and breast carcinoma: Trastuzumab, a drug with successful implications in targeted therapy, shows an antitumor effect on breast cancer with HER2 overexpression, while having no significant effect on tumors with normal HER2 expression (Cameron et al., 2017; Tolaney et al., 2019; Derakhshani et al., 2020).